Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01001338 · ClinicalTrials.gov registry record · Phase 2
Allopurinol Combination Study
A Phase 2 study, sponsored by Ardea Biosciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 227
- Enrollment target
NCT01001338: Completed Phase 2 study, sponsored by Ardea Biosciences.
NCT01001338 is a Phase 2 study that has completed, run by Ardea Biosciences. The registered enrollment target is 227 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (71% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01001338, a Phase 2 study, has completed, sponsored by Ardea Biosciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 227 participants
- Enrollment target
Study Summary
To compare the proportion of subjects whose serum urate (sUA) levels are \< 6.0 mg/dL following 4 weeks of continuous treatment of RDEA594 in combination with allopurinol to allopurinol alone in subjects with documented inadequate hypouricemic response with standard doses of allopurinol.
Interventions
- DRUG Placebo
- DRUG Allopurinol
- DRUG RDEA594
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 227 participants |
| Start Date | 2009-10 |
| Est. Completion | 2016-08 |
| Phase | Phase 2 |
What the finished NCT01001338 record still lists
NCT01001338 is an interventional study that assigns participants to a tested intervention. The registered 227 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (71% higher).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01001338 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01001338 about?
NCT01001338 is a clinical study titled "Allopurinol Combination Study". To compare the proportion of subjects whose serum urate (sUA) levels are \< 6.0 mg/dL following 4 weeks of continuous treatment of RDEA594 in combination with allopurinol to allopurinol alone in subjects with documented inadequate hypouricemic response with standard doses of allopurinol.
What is the current status of trial NCT01001338?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 227 participants. The study started on 2009-10. Estimated completion is 2016-08.
What interventions are being tested in trial NCT01001338?
The interventions under investigation include: Placebo (DRUG), Allopurinol (DRUG), RDEA594 (DRUG).
Who is sponsoring clinical trial NCT01001338?
This trial is sponsored by Ardea Biosciences, which has 32 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01001338's enrollment target sits among peer trials
227 265th of 2000 higher than 1,734 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04751409 · 227 participants · Phase 2
Evaluating the Impact of Limited Compared With Intense Post-Operative Surveillance on Patient-Reported Outcomes in Patients With Stage II-III Soft Tissue Sarcoma of the Trunk and Extremities
- NCT05742360 · 227 participants
Effect of CPAP on Blood Pressure in Excessively Sleepy Obstructive Sleep Apnea Subtype
- NCT05890352 · 227 participants · Phase 2
Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment
- NCT05107908 · 228 participants · NA
Neuronal and Behavioral Effects of an Implicit Priming Approach to Improve Eating Behaviors in Obesity
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia